Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below Two Hundred Day Moving Average – What’s Next?

Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.35 and traded as low as $2.31. Oramed Pharmaceuticals shares last traded at $2.33, with a volume of 30,850 shares.

Analyst Ratings Changes

Separately, StockNews.com lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 19th.

Oramed Pharmaceuticals Trading Down 2.5 %

The stock has a fifty day simple moving average of $2.30 and a 200-day simple moving average of $2.35. The stock has a market cap of $92.72 million, a price-to-earnings ratio of 20.91 and a beta of 1.61.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. World Equity Group Inc. bought a new stake in Oramed Pharmaceuticals in the 4th quarter valued at $48,000. XTX Topco Ltd raised its position in shares of Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 9,242 shares during the last quarter. Marquette Asset Management LLC bought a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at about $81,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Oramed Pharmaceuticals during the third quarter worth about $272,000. Finally, Dimensional Fund Advisors LP increased its stake in Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 70,190 shares during the period. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.